The First Impact Factor of Cancer Drug Resistance: 3.7

Clarivate officially released the latest edition of the Journal Citation Reports (JCR) on June 28, 2023. We are thrilled to announce that Cancer Drug Resistance (CDR) has received its first impact factor: 3.7. This significant milestone not only recognizes the remarkable progress made by CDR, but also serves as compelling evidence of CDR's commitment to publishing high-quality articles.

We extend our sincere gratitude to all those who have contributed to the success of Cancer Drug Resistance, including our esteemed Editorial Board members, Guest Editors, authors, reviewers, and loyal readers. Your continuous support has been crucial in driving the development of the journal.

Since its inception, CDR has adhered to the principles of high-quality international publishing, dedicated to providing excellent academic research for researchers worldwide. Moving forward, CDR remains steadfast in its commitment to maintaining high standards in publishing, offering more professional services, and providing a premier platform for academic exchange. Our unwavering ambition is to become an internationally renowned academic journal in the field of cancer drug resistance, making greater contributions to advancing scientific research and clinical practice in this domain.

We once again express our gratitude to everyone who has played a part in our journey and invite you to join us in celebrating this momentous occasion for CDR.